Capricor is actively enrolling our #ClinicalTrial in #DuchenneMuscularDystrophy. We currently have multiple sites initiated and open for enrollment and expect to have all 12 sites open and enrolling soon. learn more at hope2trial.com | #DMD

The HOPE-2 trial is focusing on later stage patients that are nearly or already non-ambulatory & are looking to improve skeletal muscle function using the performance of the upper limb as an indicator. #DMD #Duchenne

Capricor is delighted to join in on bringing awareness to #WorldDuchenneDay 2018. The HOPE-2 #ClinicalTrial for #DMD is open for enrollment at several sites nationwide. For more info on the #HOPEtrial please visit hope2trial.com #WDAD18 #FightDMDTogether #Duchenne

We are deeply saddened by the passing of Dr. Ronald Victor. He was a respected friend & a colleague who was the principal investigator for Capricor’s first clinical trial of its novel cell therapy, CAP-1002, in #Duchenne. We extend our sympathies to his wife, Vicki, & his family.

Capricor is a proud member of Parent Project Muscular Dystrophy (PPMD) DDDR, a group of over 40 partners, engaged in developing therapeutics for #Duchenne. The goal is to accelerate the development of meaningful treatments for #DuchenneMuscularDystrophy through open discussion and collaboration.

Capricor is at the 20th Annual SoCalBio Conference this weekend in Long Beach, CA! The #SoCalBioConference showcases Southern California value-based #bioscience innovations and explores efficient pathways to bring them to market. Learn more HERE -> buff.ly/2R7YUC7

An inspiring image created by a 14-year-old boy with #Duchenne. With the HOPE-2 #ClinicalTrial for #DMD we are attempting to advance the study of and possible treatments for #DuchenneMuscularDystrophy. Please go to duchenneclinicaltrial.com to learn more about the study.

Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy

Don't miss me present at the @PiperJaffrayCo Healthcare Conference this Wednesday, Nov 29 at 11:50 a.m. ET. Catch the webcast here --> goo.gl/3P6E6B

The U.S. Food and Drug Administration (FDA) has cleared Capricor's Investigational New Drug (IND) application to conduct a new clinical trial of CAP-1002, our lead investigational therapy, in boys and young men in advanced stages of #DuchenneMuscularDystrophy

Find me quoted in HuffPost "A Breakthrough in Duchenne Muscular Dystrophy" #Duchenne #DMD #BioTech Read More - goo.gl/uCMD1f

Capricor Therapeutics Announces Issuance of Key U.S. Patent on #ExosomeTechnology Read More - buff.ly/2CbQd21

Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies Read More - buff.ly/2Dc4mfM

These new patent applications expand the scope of the Exclusive License Agreements with Cedars to enable Capricor to develop new therapeutic indications for cellular & #exosome therapies in #DuchenneMuscularDystrophy, ventricular tachyarrhythmia, cancer & age-related disorders.

#DuchenneMuscularDystrophy is a progressive disease afflicting approx 200K boys & young men. Capricor recently reported significant improvements in cardiac & skeletal muscle function in patients with advanced stages of #DMD following a single, intracoronary dose of CAP-1002.

Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for #DuchenneMuscularDystrophy Therapy. Read More - buff.ly/2E5aXxi

Capricor to Host Key Opinion Leader Lunch on March 9 Read More - buff.ly/2FFru8K

February 28th, 2018 is #RareDiseaseDay - Raising awareness for patients, families, & carers around the world that are affected by rare diseases. #DMD Rare Disease Day

Don't miss leading researchers & advocate for #DMD discuss emerging paradigms in treatment! Presentations will be from 11am-1pm EST on Fri, March 9 Call 866-717-4562 (US) & 210-874-7812 (int) & enter ID: 5567179 Join via webcast - buff.ly/2tqtIq7

The Capricor team at the ‘18 #MDAClinicCon. Thank you to those who stopped by to learn more about the HOPE-2 Clinical Trial for #DuchenneMuscularDystrophy